GIC, Temasek and TPG Capital to invest in Novotech.

GIC, a global investment firm, Temasek, a Singaporean state-owned multinational investment firm, and TPG Capital, a global alternative asset management firm, agreed to invest in Novotech, a full-service clinical research organization and scientific advisory company. Financial terms were not disclosed. “Novotech is already on its way to be a major global player in the CRO space, with 3,000 employees and experience across more than 6,000 clinical projects. We are excited by the new support of GIC and Temasek, and the continued support of TPG, as we continue to scale the business while maintaining our high-quality standards," John Moller, Novotech CEO.